108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
东北非小细胞肺癌患者 KRAS G12C 的患病率和并发致病性突变
Authors Liu Y, Li H, Zhu J, Zhang Y, Liu X, Li R, Zhang Q, Cheng Y
Received 23 September 2020
Accepted for publication 17 February 2021
Published 15 March 2021 Volume 2021:13 Pages 2447—2454
DOI https://doi.org/10.2147/CMAR.S282617
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Beicheng Sun
Objective: KRAS mutation is one of important driver genes in non-small-cell lung cancer (NSCLC) and the patients with KRAS G12C mutations benefit from the inhibitor AMG510. However, the frequency, concurrent pathogenic mutations, and clinical characteristic of KRAS G12C is unknown in the NSCLC population of Northeast China.
Methods: The retrospective analysis was derived from 431 NSCLC patients in Jilin Cancer Hospital between January 2018 and June 2019. The mutation frequency and concurrent mutations of KRAS G12C in tumor or peripheral blood was detected by next-generation sequencing (NGS).
Results: The RAS mutant rate was observed in 10.7% (46/431) of this cohort. All RAS -driver cancers are caused by mutations in the KRAS isoform, while the NRAS and HRAS isoforms were not detected. Among KRAS -mutant patients, 42 (91.3%) showed exon 2 mutation in 12 codon and 13 codon. KRAS G12C showed a 4.6% (20/431) mutation rate in this cohort and the highest frequency (43.5%, 20/46) in KRAS -mutant-positive patients. There was no difference between tumor tissue and plasma in terms of either KRAS or KRAS G12C mutation. The most frequent co-occurrence mutations with KRAS G12C were TP53 , followed by PTEN . Furthermore, KRAS G12C was exclusive with STK11 mutation. KRAS G12C mutation was associated with age, disease stage, and smoking status (P =0.024; P =0.02; P =0.006), smoking remained an independent factor for KRAS G12C mutation (P =0.037), and higher mutation frequency in patients older than 60, stage I–III, or smoking in NSCLC (P =0.0151, P =0.0343, P =0.0046, respectively).
Conclusion: KRAS mutation was the only isoforms of RAS family, of these 43.5% harbored the KRASG12C subtype in northeastern Chinese NSCLC patients. KRAS G12C is associated with age, pathological stage and smoking status, more commonly harbored TP53 /PTEN mutations, and providing more genome profile for targeted therapy in local clinical practice.
Keywords: next-generation sequencing, non-small-cell lung cancer, KRAS G12C , tissue, plasma, mutations